{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:12:50Z","timestamp":1790903570210,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objects<\/jats:title><jats:p>The aim of this study is to explore the epidemiological characteristics of peripheral T-cell lymphoma in Beijing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>\u00a0All data were extracted from the Beijing Cancer Registry database from January 1, 2007, to December 31, 2018. Segi\u2019s World Standard Population was used to estimate the age-standardized rate (ASR). Changes in trends were examined using joinpoint regression analysis. The observed survival was estimated by the Kaplan\u2013Meier method. Relative survival was calculated using Ederer II and standardized using the Brenner method and International Cancer Survival Standard (ICSS) group 1 age structure. Stratified by gender, area, and histological type, incidence, mortality, and age of onset trends were observed in Beijing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>\u00a0In Beijing, there were 801 new cases and 463 deaths of T-cell lymphoma from 2007 to 2018. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) was the most prevalent subtype (37.45%), followed by angioimmunoblastic T-cell lymphoma (AITL; 20.35%), NK\/T-cell lymphoma (NK\/TCL; 17.60%), and anaplastic large cell lymphoma (ALCL; 10.24%). The crude incidence and mortality rates were 0.52 and 0.30 per 100,000 person-years, respectively, whereas the age-standardized incidence and mortality rates (ASIR and ASMR) were 0.35 and 0.18 per 100,000 person-years, respectively. Both ASIR and ASMR were more prevalent in men (0.48 and 0.24 per 100,000) and urban area (0.38 and 0.19 per 100,000) than in women (0.22 and 0.11 per 100,000) and rural area (0.30 and 0.15 per 100,000). The average annual percentage change (AAPC) of ASIR and ASMR was 5.72% (95% confidence interval (CI): 1.79%\u20139.81%) and 4.35% (95% CI: \u22120.09%\u20138.99%), respectively. The age-specific incidence rate increased with age and peaked at the age groups of 10\u201314 and 80\u201384. The mean and median age of onset increased between 2007 and 2018. In addition, it decreased after the age of onset was age standardization (<jats:italic>\u03b2 = \u22120.41<\/jats:italic>, <jats:italic>P = 0.26<\/jats:italic>). The 5-year age-standardized relative survival was 39.02% for all patients, 58.14% for NK\/TCL, 57.60% for ALCL, 31.38% for AITL, and 29.18% for PTCL-NOS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>\u00a0T-cell lymphoma incidence was rising, but survival was dismal in Beijing, indicating the need for improved early diagnosis and standardized treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.863269","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:30:15Z","timestamp":1657690215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of Lymphoma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B2","unstructured":"FerlayJ\n            ErvikM\n            LamF\n            ColombetM\n            MeryL\n            Pi\u00f1erosM\n          Lyon, FranceInternational Agency for Research on CancerGlobal Cancer Observatory: Cancer Today2020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-2870.2012.02.006","article-title":"The Chinese Lymphoma Study Group. Distribution Pattern of Lymphoma Subtypes in China: A Nationwide Multicenter Study of 10 002 Cases","volume":"11","author":"Li","year":"2012","journal-title":"J Diagn Concepts Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma Incidence, Survival and Prevalence 2004\u20132014: Sub-Type Analyses From the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1805","article-title":"Epidemiology and Secular Trends of Malignant Lymphoma in Japan: Analysis of 9426 Cases According to the World Health Organization Classification","volume":"7","author":"Muto","year":"2018","journal-title":"Cancer Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4132\/KoreanJPathol.2011.45.3.254","article-title":"WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study","volume":"45","author":"Kim","year":"2011","journal-title":"J Pathol Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205217","article-title":"Uncommon Variants of Mature T-Cell Lymphomas (MTCLs): Imaging and Histopathologic and Clinical Features With Updates From the Fourth Edition of the World Health Organization (WHO) Classification of Lymphoid Neoplasms","volume":"13","author":"Salem","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B11","first-page":"54 p","volume-title":"L. Cancer Registratiion: Principles and Methods","author":"Jensen","year":"1991"},{"key":"B12","volume-title":"International Rules for Multiple Primary Cancers (ICD-O Third Edition)","year":"2004"},{"key":"B13","volume-title":"Check and Conversion Programs for Cancer Registries (IARC\/IACR Tools for Cancer Registries) IARC Technical Report No. 42","author":"Ferlay","year":"2005"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.093","article-title":"Nationwide Statistical Analysis of Lymphoid Malignancies in Korea","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.clml.2020.05.010","article-title":"Influence of Rurality, Race, and Ethnicity on Non-Hodgkin Lymphoma Incidence","volume":"20","author":"Blansky","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042762","article-title":"Urban-Rural Disparity in Cancer Incidence in China, 2008-2012: A Cross-Sectional Analysis of Data From 36 Cancer Registers","volume":"11","author":"Yuan","year":"2021","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00579","article-title":"Urban-Rural Disparity in Cancer Incidence, Mortality, and Survivals in Shanghai, China, During 2002 and 2015","volume":"8","author":"Li","year":"2018","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The Outcome of Peripheral T-Cell Lymphoma Patients Failing First-Line Therapy: A Report From the Prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.750323","article-title":"A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.732727","article-title":"Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis","volume":"8","author":"Du","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21589","article-title":"The Rapidly Changing Landscape in Mature T-Cell Lymphoma (MTCL) Biology and Management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29477","article-title":"Advance and Stagnation in the Treatment of Patients With Lymphoma and Myeloma: Analysis Using Population-Based Cancer Registry Data in Japan From 1993 to 2006","volume":"137","author":"Chihara","year":"2015","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3037","article-title":"Improving Survival of 3760 Patients With Lymphoma: Experience of an Academic Center Over Two Decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","article-title":"Mortality of Lymphoma and Myeloma in China, 2004-2017: An Observational Study","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3760\/cma.j.issn.0253-9624.2018.06.007","article-title":"Analysis on the Trend of Cancer Incidence and Age Change in Cancer Registry Areas of China, 2000 to 2014","volume":"52","author":"Zheng","year":"2018","journal-title":"Chin J Prev Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.863269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:30:21Z","timestamp":1657690221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.863269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.863269"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.863269","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"article-number":"863269"}}